Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by University of Rostock.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
University of Rostock
ClinicalTrials.gov Identifier:
NCT00947908
First received: July 27, 2009
Last updated: January 12, 2010
Last verified: July 2009
  Purpose

Dendritic cells (DC) play a key role in the pathogenesis of allergic diseases. The regulation of blood dendritic cells in patients with hymenoptera venom allergy before and during immune therapy is unknown.


Condition Intervention
Hymenoptera Venom Allergy
Biological: Hymenoptera venom

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Regulation of Blood Dendritic Cells During Immune Therapy for Hymenoptera Venom Allergy

Resource links provided by NLM:


Further study details as provided by University of Rostock:

Primary Outcome Measures:
  • Number of myeloid DC and plasmacytoid DC in peripheral blood [ Time Frame: Directly before, 1 hour after, and 12 months after initiation of immune therapy ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Surface molecule expression on myeloid DC and plasmacytoid DC [ Time Frame: Directly before, 1 hour after, and 12 months after initiation of immune therapy ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: June 2009
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
Biological: Hymenoptera venom
Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).

  Eligibility

Ages Eligible for Study:   16 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with diagnosed hymenoptera venom allergy
  • No previous treatments for hymenoptera venom allergy

Exclusion Criteria:

  • Treatment with immunosuppressive agents
  • Any malignant disease
  • Infections within 1 week prior to the initiation of the treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00947908

Locations
Germany
University of Rostock
Rostock, mecklenburg-Vorpommern, Germany, 18057
Sponsors and Collaborators
University of Rostock
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: PD Dr. Marek Lommatzsch, University of Rostock
ClinicalTrials.gov Identifier: NCT00947908     History of Changes
Other Study ID Numbers: LO-0004
Study First Received: July 27, 2009
Last Updated: January 12, 2010
Health Authority: Germany: Ethics Commission

Keywords provided by University of Rostock:
Hymenoptera venom allergy
Dendritic cells (DC)

Additional relevant MeSH terms:
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on November 20, 2014